Seres Therapeutics Files 8-K on Financials

Ticker: MCRB · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1609809

Seres Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySeres Therapeutics, Inc. (MCRB)
Form Type8-K
Filed DateAug 13, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, sec-filing

TL;DR

SERES filed an 8-K, expect financial updates soon.

AI Summary

On August 13, 2024, Seres Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or operational updates were detailed in the provided text excerpt.

Why It Matters

This filing indicates Seres Therapeutics is providing updates on its financial condition and operational results to the SEC, which is important for investors to monitor the company's performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting financial condition and results of operations, with no immediate negative or positive news indicated in the provided text.

Key Players & Entities

  • Seres Therapeutics, Inc. (company) — Registrant
  • August 13, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 001-37465 (identifier) — Commission File Number
  • 27-4326290 (identifier) — IRS Employer Identification No.
  • Cambridge, MA (location) — Principal Executive Offices
  • 617-945-9626 (phone_number) — Registrant's telephone number

FAQ

What specific financial information is being reported by Seres Therapeutics in this 8-K?

The provided text states the 8-K concerns 'Results of Operations and Financial Condition' but does not detail specific financial figures.

When was this 8-K filing submitted?

The filing was submitted on August 13, 2024.

What is the Commission File Number for Seres Therapeutics?

The Commission File Number for Seres Therapeutics is 001-37465.

In which state is Seres Therapeutics incorporated?

Seres Therapeutics is incorporated in Delaware.

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on the company's results of operations and financial condition, as well as Regulation FD disclosures and financial statements.

Filing Stats: 1,534 words · 6 min read · ~5 pages · Grade level 13.6 · Accepted 2024-08-13 07:05:33

Key Financial Figures

  • $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following Exhibits 99.1 and 99.2 relate to Items 2.02 and 7.01, respectively, and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Seres Therapeutics, Inc. Press Release issued August 13, 2024 99.2 Seres Therapeutics, Inc. Corporate Presentation as of August 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Important Additional Information About the Transaction and Where to Find It This communication is being made in respect of the proposed transaction involving Seres and SPN. Seres intends to file with the Securities and Exchange Commission (the " SEC "), a proxy statement and other relevant documents in connection with a special meeting of Seres' stockholders for purposes of obtaining, stockholder approval of the proposed transaction. The definitive proxy statement will be sent or given to the stockholders of Seres and will contain important information about the proposed transaction and related matters. INVESTORS AND STOCKHOLDERS OF SERES ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SERES AND THE PROPOSED TRANSACTION. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Seres with the SEC at the SEC's website at www.sec.gov or from Seres at its website at ir.serestherapeutics.com. Participants in the Solicitation Seres and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Seres' stockholders in connection with the proposed transaction will be

Forward-Looking Statements

Forward-Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the financial terms, timing and completion of the sale of VOWST assets to SPN; the receipt of future payments and the use of proceeds of the transaction,; the timing and results of our clinical studies and data readouts; future product candidates, development plans and commercial opportunities; operating plans and our future cash runway; our ability to generate additional capital; our planned strategic focus; anticipated timing of any of the foregoing and other statements which are not historical fact. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) we have incurred significant losses, are not currently profitable and may never become profitable; (2) our need for additional funding; (3) our history of operating losses; (4) the restrictions in our debt agreement; (5) our novel approach to therapeutic intervention; (6) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (7) the competition we will face; our ability to protect our intellectual property; (8) our ability to retain key personnel and to manage our growth; (9) the occurrence of any event, change or other circumstance that could give rise to the termination of the Purchase Agreement; (10) our failure to obtain stockholder a

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: August 13, 2024 By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.